MPO and influenza: While both validation of TG6-44 treatment on MPO-mediated ROS inhibition as well its effect on the course of influenza infection in an in vivo model remain as the immediate goal of our investigations, it is however evident from our current findings that the strategy of MPO inhibition using quinazolin derivatives such as TG6-44 may be helpful in diminishing immune mediated injury seen during influenza A virus infections.